protein degradation

BMS dumps $100M degrader-antibody conjugate over ph. 1 data

BMS has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.

Nick Paul Taylor Sep 18, 2026 3:41am

Roche bets $700M upfront on Nurix’s late-phase BTK degrader

Jun 8, 2026 4:41am

French biotech pens $128M deal for Kezar protein degrader work

Mar 12, 2026 9:00am

plan B fail reroute road path trail miss

Cullgen ditches reverse merger with Pulmatrix to go with Gyre

Mar 2, 2026 10:55am

J&J, Google venture arms line up to back EpiBiologics' series B

Jan 8, 2026 9:05am

Various shades of blue sewing thread spools

Amgen weaves in UK biotech with up to $840M acquisition

Jan 6, 2026 10:35am